查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929603

二十碳五烯酸乙酯（Icosapentaethyl）醫藥市場按產品類型、年齡層、適應症、用途、分銷管道和最終用戶分類的全球預測（2026-2032年）

Icosapent Ethyl Drugs Market by Product Type, Patient Age Group, Indication, Application, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，二十碳五烯酸乙酯製藥市值將達到 16.3 億美元，到 2026 年將成長至 17.5 億美元，到 2032 年將達到 25.6 億美元，年複合成長率為 6.66%。

關鍵市場統計數據
基準年 2025 16.3億美元
預計年份：2026年 17.5億美元
預測年份 2032 25.6億美元
複合年成長率 (%) 6.66%

為相關人員提供一份簡明扼要的概述，闡述正在重塑二十碳五烯酸乙酯治療格局的臨床、監管、生產和商業性因素。

臨床證據的不斷累積、法規結構的不斷改進以及支付方日益嚴格的審查，共同促使二十碳五烯酸（EIPA）成為現代心血管治療的焦點。隨著臨床醫師重新評估殘餘心血管風險和三酸甘油酯管理策略，高純度EIPA製劑的治療特性促使人們重新關注其在二級預防和血脂管理方面的應用。同時，生產商和供應商在規模化生產、品管以及循證定位等方面也面臨新的挑戰，以滿足臨床和商業性預期。

加速臨床證據、支付方期望和生產現代化將如何重塑二十碳五烯酸乙酯療法的戰略格局

二十碳五烯酸乙酯的治療和商業性格局正在經歷一場變革，其促進因素包括數據的成熟、監管的完善以及處方模式的轉變。大量心血管結局研究正在闡明該藥物在傳統降血脂治療之外，如何有效應對殘餘風險，促使臨床醫生重新評估二級預防策略。隨著證據的積累，專業指南和學會越來越重視對患者的精細化選擇，強調採用分層方法，優先考慮那些儘管接受了最佳化的他汀類藥物治療，但仍高三酸甘油脂血症和心血管風險升高的患者。

評估供應鏈、採購和商業性對2025年累積關稅調整（導致跨國藥品成本上升）的因應措施

2025年生效的關稅政策變更為參與國際價值鏈的醫藥相關人員帶來了複雜的成本和供應問題。進口關稅和貿易法規的調整會影響原料藥採購、製劑生產和跨境分銷的經濟效益。對於依賴特殊原料或外包委託製造流程的產品而言，關稅導致的成本波動可能促使企業重新談判供應商合約、重新評估其供應鏈佈局，並考慮近岸外包或區域化策略以降低風險。

了解製劑形式、給藥途徑、劑型、適應症、通路、年齡層和最終用戶群如何相互交織，從而影響二十碳五烯酸乙酯的臨床應用和可及性。

基於細分市場的洞察揭示了二十碳五烯酸乙酯計畫的臨床效用、患者可及性和營運執行之間的交集。軟膠囊劑型符合既定的口服降血脂治療給藥方案，有助於提高病患遵從性，並方便門診病患取藥。口服給藥方式便於門診病人使用，規範給藥方案，並可整合到慢性病管理路徑中，透過門診就診和藥房續藥來監測處方箋。

美洲、歐洲、中東和非洲以及亞太地區的區域差異將影響二十碳五烯酸乙酯的監管路徑、支付方行為和市場接受度模式。

區域特徵將對二十碳五烯酸乙酯的監管解讀、支付方接受度、生產策略和臨床應用產生深遠影響。美洲地區是一個多元化的環境，監管機構、支付系統和專科藥房在此互動，共同製定病患治療路徑。遵循臨床指引和基於療效的支付方談判在此尤為重要。該地區的商業性策略通常強調循證價值提案和將臨床終點與報銷機制掛鉤的合作合約模式。

評估藥物研發公司、契約製造、臨床研究人員、支付方和專業經銷商組成的生態系統，影響著產品的可及性和生命週期執行。

二十碳五烯酸乙酯市場的競爭和策略定位反映了藥物研發公司、臨床證據管理機構、契約製造和專業供應合作夥伴之間的相互作用。藥物研發公司透過開發、檢驗和傳播結果數據，為臨床可信度奠定了基礎，這些數據能夠指導處方行為和與支付方的溝通。同時，契約製造商和活性藥物原料藥供應商在擴大產能、品管和成本效益方面發揮關鍵作用，尤其是在口服軟膠囊生產方面，因為口服軟膠囊的生產需要專業的包封技術和穩定性方面的專業知識。

為加強證據產生、供應鏈韌性、支付方合作、通路最佳化和病患支持，經營團隊應採取具體策略行動和改善營運措施。

尋求增強競爭優勢的領導者應優先考慮一系列應對當前關鍵挑戰的戰術性和策略措施。首先，應投資於有針對性的證據生成，例如真實世界療效研究、患者報告結局以及符合支付方要求的衛生經濟學分析，以補充核心結局試驗。這些舉措的設計應旨在為處方集、報銷談判和基於價值的契約討論提供資訊，同時解決臨床醫生對結果普遍適用性和長期安全性的擔憂。

結合臨床數據、監管資訊、專家定性訪談和供應鏈評估的嚴謹多源研究途徑，確保了研究結果的可靠性和檢驗。

本報告的研究整合了多方面的證據，從而對二十碳五烯酸乙酯的體內分佈進行了全面、深入的分析。主要內容包括對同儕審查的臨床文獻進行系統性回顧、分析監管核准文件和藥品附加檔，以及綜合分析藥物警戒和安全性報告。此外，還採訪了心臟病學、脂質代謝、藥房營運和衛生經濟學等領域的關鍵專家，從臨床和監管觀點出發，為實際應用和決策提供臨床實踐層面的背景資訊。

一份簡潔的綜合分析報告重點闡述了證據、支付方合作以及穩健的供應鏈將如何決定二十碳五烯酸乙酯的長期臨床應用和商業性成功。

總之，二十碳五烯酸乙酯在現代心血管治療中佔據戰略地位，兼具臨床療效、安全性和基於價值的定位。該療法的未來發展將受到持續的核准後證據累積、支付方將臨床結果與經濟終點緊密結合的策略以及降低成本和供應風險的供應鏈調整的影響。積極圍繞這些關鍵優先事項調整其臨床開發、生產計劃和商業化工作的相關人員，將更有利於成功管理准入途徑，並實現其臨床和商業目標。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 二十碳五烯酸乙酯藥物市場（依產品類型分類）

  • 純二十碳五烯酸乙酯產品
    • 乙酯膠囊
    • 乙酯軟膠囊
  • 複合產品
    • 含他汀類藥物的二十碳五烯酸乙酯製劑
    • 與其他降血脂藥物併用：二十碳五烯酸乙酯
  • 研究和分發產品
    • 臨床試驗用品
    • 複方製劑

9. 依患者年齡層分類的二十碳五烯酸乙酯藥物市場

  • 成人版
  • 老年人

第10章 二十碳五烯酸乙酯藥物市場（依適應症分類）

  • 降低心血管風險
    • 動脈粥狀硬化性心血管疾病
    • 伴隨心血管危險因子的糖尿病
  • 高三酸甘油脂血症
    • 嚴重高三酸高三酸甘油脂血症
    • 輕度至中度高高三酸甘油脂血症

第11章 二十碳五烯酸乙酯藥物市場（依應用分類）

  • 降低心血管風險
  • 高三酸甘油脂血症

第12章 二十碳五烯酸乙酯藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 二十碳五烯酸乙酯藥物市場（依最終用戶分類）

  • 診所
  • 居家照護
  • 醫院

第14章 二十碳五烯酸乙酯製藥市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 二十碳五烯酸乙酯類藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國二十碳五烯酸乙酯藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國二十碳五烯酸乙酯製藥市場

第18章 中國二十碳五烯酸乙酯醫藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alembic Pharmaceuticals Ltd.
  • Amarin Corporation plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Himalaya Global Holdings Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Ltd.
Product Code: MRR-0A3806951846

The Icosapent Ethyl Drugs Market was valued at USD 1.63 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 6.66%, reaching USD 2.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.63 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.56 billion
CAGR (%) 6.66%

A concise orientation to the clinical, regulatory, manufacturing, and commercial forces that are redefining the icosapent ethyl therapeutic landscape for stakeholders

Icosapent ethyl has emerged as a focal point in contemporary cardiovascular therapeutics, driven by a convergence of clinical evidence, evolving regulatory frameworks, and heightened payer scrutiny. As clinicians reassess strategies for residual cardiovascular risk and triglyceride management, the therapeutic profile of highly purified eicosapentaenoic acid preparations invites renewed consideration across secondary prevention and lipid management pathways. Concurrently, manufacturers and suppliers face fresh imperatives around scalability, quality controls, and evidentiary positioning to meet both clinical and commercial expectations.

This introduction frames the subsequent analysis by outlining the core dimensions that influence product development and adoption. Clinical outcomes and safety data form the foundation for therapeutic credibility, while regulatory determinations and label language shape prescribing practice and reimbursement. Manufacturing robustness and supply chain resilience determine commercial availability, and distribution strategies influence point-of-care access. Taken together, these vectors create a complex environment in which stakeholders must navigate scientific nuance, payer evidence requirements, and operational realities. The remainder of the executive summary builds on this foundation to explore transformative shifts, tariff impacts, segmentation intelligence, regional dynamics, competitive positioning, actionable recommendations, and methodological rigor.

How converging clinical evidence, payer expectations, and manufacturing modernization are reshaping the strategic environment for icosapent ethyl therapeutics

The therapeutic and commercial landscape for icosapent ethyl is undergoing transformative shifts fueled by data maturation, regulatory refinements, and changing prescribing paradigms. Robust cardiovascular outcomes research has crystallized the drug's role in addressing residual risk beyond conventional lipid-lowering therapies, prompting clinicians to re-evaluate secondary prevention strategies. As evidence has accumulated, professional guidelines and specialty societies have increasingly engaged with the nuances of patient selection, emphasizing stratified approaches that prioritize individuals with persistent hypertriglyceridemia and elevated cardiovascular risk despite optimized statin therapy.

Concurrently, payer frameworks are tightening their evidentiary expectations, placing greater emphasis on real-world effectiveness, cost-effectiveness analyses, and outcomes-based contracting. This shift compels manufacturers to generate post-approval evidence and to develop targeted value narratives that align clinical benefits with economic endpoints. On the supply side, pharmaceutical manufacturers and contract partners are investing in capacity expansion, analytical method validation, and enhanced quality-by-design practices to ensure consistent product availability and to meet tighter regulatory scrutiny. These convergent forces are accelerating strategic collaborations across clinical, commercial, and manufacturing domains, reshaping how icosapent ethyl is positioned, prescribed, and delivered to patients.

Assessing the supply chain, procurement, and commercial responses to the cumulative tariff adjustments that elevated cross-border pharmaceutical costs in 2025

Tariff policy shifts enacted in 2025 have introduced a complex layer of cost and supply considerations for pharmaceutical stakeholders operating across international value chains. Adjustments to import duties and trade regulations affect the economics of active pharmaceutical ingredient sourcing, finished dosage form manufacturing, and cross-border distribution. For products dependent on specialized raw materials or outsourced manufacturing nodes, tariff-induced cost variability can prompt renegotiation of supplier contracts, reassessment of supply chain footprints, and consideration of nearshoring or regionalization strategies to mitigate exposure.

In practical terms, manufacturers and distributors are evaluating whether to absorb incremental costs, pass them through to downstream purchasers, or modify sourcing strategies to preserve competitiveness. Procurement teams are intensifying supplier diversification efforts and increasing inventory planning sophistication to manage lead-time uncertainty. At the same time, regulatory filings and compliance documentation must adapt to reflect any changes in manufacturing location or ingredient provenance. Taken together, the cumulative tariff landscape in 2025 acts as a catalyst for structural adjustments across supply chains, commercial agreements, and manufacturing strategies, reinforcing the need for resilient, flexible planning that anticipates future trade volatility.

Uncovering how dosage form, route, strength, indication, channel, age group, and end-user segmentation converge to shape clinical use and access for icosapent ethyl

Segmentation-driven insight reveals where clinical utility, patient access, and operational execution intersect for icosapent ethyl programs. The product's formulation in softgel capsule form aligns with established oral lipid therapy delivery conventions, supporting patient adherence and straightforward dispensing at outpatient touchpoints. Oral administration facilitates use in ambulatory populations and enables integration into chronic care pathways where dosing regimens can be standardized and adherence monitored through clinic visits and pharmacy refills.

Strength differentiation between 1000 milligram and 500 milligram presentations allows prescribers to tailor regimens to patient needs and to accommodate titration strategies rooted in clinical judgment and lipid response. Application segmentation distinguishes between cardiovascular risk reduction and management of hypertriglyceridemia, highlighting the dual clinical pathways that underpin utilization discussions and value communication. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacy outlets, each presenting distinct fulfillment, patient counseling, and reimbursement interactions. Patient age group segmentation into adult and geriatric cohorts underscores the need for safety monitoring, polypharmacy considerations, and adherence support tailored to older adults. Finally, end-user segmentation across clinic, home care, and hospital settings illuminates different care pathways, monitoring intensity, and supply logistics, all of which influence patient access and clinical outcomes.

Regional nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory pathways, payer dynamics, and adoption patterns for icosapent ethyl

Regional dynamics exert a profound influence on regulatory interpretation, payer receptivity, manufacturing strategy, and clinical adoption of icosapent ethyl. The Americas present a heterogeneous landscape where regulatory authorities, payer systems, and specialty pharmacies interact to define patient pathways; here, clinical guideline engagement and outcomes-focused payer negotiations are particularly consequential. Within this region, commercial approaches often emphasize evidence-based value propositions and collaborative contracting models that align clinical endpoints with reimbursement mechanisms.

Europe, Middle East & Africa encompass jurisdictions with diverse regulatory requirements and health technology assessment frameworks, creating a patchwork of access scenarios. Manufacturers operating in this region must navigate variations in pricing negotiations, reimbursement timelines, and clinical guideline incorporation while also considering local manufacturing or importation strategies to manage cost pressures. Asia-Pacific includes rapidly evolving markets with expanding chronic disease burdens and increasing sophistication in clinical research infrastructure. In many Asia-Pacific countries, growing investment in cardiovascular prevention, expanding specialty pharmacy networks, and evolving payer mechanisms create opportunities for differentiated engagement, though local regulatory and distribution complexities require tailored market entry and lifecycle management tactics.

Evaluating the ecosystem of originators, contract manufacturers, clinical investigators, payers, and specialty distributors that shape product access and lifecycle execution

Competitive and strategic positioning within the icosapent ethyl arena reflects the interplay of originator companies, clinical evidence stewards, contract manufacturers, and specialty supply partners. Originator sponsors have anchored clinical credibility by developing, validating, and disseminating outcome data that inform prescribing behavior and payer dialogues. At the same time, contract manufacturing organizations and active pharmaceutical ingredient suppliers play a critical role in capacity scaling, quality management, and cost-efficiency, particularly for oral softgel production that requires specialized encapsulation and stability expertise.

Strategic alliances between clinical investigators, academic centers, and commercial teams have been central to building the post-approval evidence base and to exploring label-adjacent indications or subpopulation benefits. Payers and pharmacy benefit managers exert influence through utilization management policies and formulary placement criteria, incentivizing stakeholders to align around value demonstration and real-world evidence generation. Finally, specialty pharmacies and integrated care networks serve as pivotal distribution and adherence support nodes, bridging clinical prescribers and patients while facilitating monitoring and patient support programs. Together, these actors form an ecosystem whose effectiveness depends on transparent data exchange, supply reliability, and coherent value communication.

Concrete strategic actions and operational improvements for executives to fortify evidence generation, supply resilience, payer engagement, channel optimization, and patient support

Leaders seeking to strengthen their competitive position should prioritize a set of tactical and strategic initiatives that respond to current imperatives. First, invest in targeted evidence generation that complements pivotal outcomes trials with real-world effectiveness studies, patient-reported outcomes, and health economic analyses tailored to payer requirements. These efforts should be designed to inform formularies, reimbursement negotiations, and value-based contracting discussions while also addressing clinician concerns about generalizability and long-term safety.

Second, pursue supply chain resilience by diversifying API sources, validating alternative manufacturing partners, and exploring regional manufacturing footprints to mitigate tariff exposure and logistical risk. Third, refine commercialization models to reflect channel-specific requirements: hospital formularies demand different value narratives and support mechanisms than retail or online pharmacy channels, and integrated patient-support services can materially influence adherence. Fourth, engage early with payers and health technology assessment bodies to align evidentiary packages with reimbursement endpoints and to explore outcomes-based arrangements where appropriate. Finally, develop targeted provider education and patient engagement programs that emphasize appropriate patient selection, adherence strategies, and monitoring protocols to maximize therapeutic benefit and support long-term uptake.

A rigorous, multi-source research approach combining clinical, regulatory, qualitative expert interviews, and operational supply assessments to ensure robust and validated findings

The research underpinning this report integrates multiple evidence streams to produce a robust, triangulated understanding of icosapent ethyl dynamics. Primary inputs include systematic reviews of peer-reviewed clinical literature, analysis of regulatory approvals and labeling texts, and synthesis of pharmacovigilance and safety reports. These clinical and regulatory perspectives are complemented by interviews with key opinion leaders across cardiology, lipidology, pharmacy practice, and health economics, providing practitioner-level context for real-world use and decision-making.

On the commercial and operational side, the methodology incorporates structured interviews with manufacturing, procurement, and distribution stakeholders, as well as assessments of supply chain configurations and manufacturing capabilities. Payer-facing insights are derived from discussions with reimbursement specialists and from public payer policy documentation, which together inform the analysis of access barriers and contracting approaches. Data synthesis followed a transparent triangulation protocol that weighted evidence by source type and recency, and iterative validation sessions with external experts were used to refine interpretations and to ensure analytical rigor.

A concise synthesis highlighting how evidence, payer alignment, and resilient supply chains will determine long-term clinical uptake and commercial success for icosapent ethyl

In conclusion, icosapent ethyl occupies a strategic niche in contemporary cardiovascular care where clinical efficacy, safety, and value-based positioning intersect. The therapeutic's trajectory will be shaped by continued post-approval evidence generation, payer engagement strategies that credibly link clinical outcomes to economic endpoints, and supply chain adaptations that mitigate cost and availability risks. Stakeholders who proactively align their clinical development, manufacturing planning, and commercialization efforts around these imperatives will be better positioned to navigate access pathways and to realize clinical and business objectives.

Sustained focus on evidence generation, thoughtful engagement with payers and providers, and disciplined supply chain management will be the differentiators that determine which organizations capture long-term clinical relevance and operational advantage. The findings in this report offer detailed directional guidance to support those efforts and to inform strategic investments, partnerships, and tactical initiatives across the development and commercialization lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Icosapent Ethyl Drugs Market, by Product Type

  • 8.1. Pure Icosapent Ethyl Products
    • 8.1.1. Ethyl Ester Capsules
    • 8.1.2. Ethyl Ester Softgels
  • 8.2. Combination Products
    • 8.2.1. Icosapent Ethyl With Statins
    • 8.2.2. Icosapent Ethyl With Other Lipid Modifiers
  • 8.3. Research And Compounding Products
    • 8.3.1. Clinical Trial Supplies
    • 8.3.2. Compounded Preparations

9. Icosapent Ethyl Drugs Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric

10. Icosapent Ethyl Drugs Market, by Indication

  • 10.1. Cardiovascular Risk Reduction
    • 10.1.1. Atherosclerotic Cardiovascular Disease
    • 10.1.2. Diabetes With Cardiovascular Risk Factors
  • 10.2. Hypertriglyceridemia
    • 10.2.1. Severe Hypertriglyceridemia
    • 10.2.2. Mild To Moderate Hypertriglyceridemia

11. Icosapent Ethyl Drugs Market, by Application

  • 11.1. Cardiovascular Risk Reduction
  • 11.2. Hypertriglyceridemia

12. Icosapent Ethyl Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Icosapent Ethyl Drugs Market, by End-User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital

14. Icosapent Ethyl Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Icosapent Ethyl Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Icosapent Ethyl Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Icosapent Ethyl Drugs Market

18. China Icosapent Ethyl Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Alembic Pharmaceuticals Ltd.
  • 19.6. Amarin Corporation plc
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Bayer AG
  • 19.9. Biocon Limited
  • 19.10. Cipla Limited
  • 19.11. Dr. Reddy's Laboratories Ltd.
  • 19.12. GlaxoSmithKline plc
  • 19.13. Glenmark Pharmaceuticals Ltd.
  • 19.14. Himalaya Global Holdings Ltd.
  • 19.15. Macleods Pharmaceuticals Ltd.
  • 19.16. Merck & Co., Inc.
  • 19.17. Mylan N.V.
  • 19.18. Novartis AG
  • 19.19. Novo Nordisk A/S
  • 19.20. Pfizer Inc.
  • 19.21. Sanofi S.A.
  • 19.22. Sun Pharmaceutical Industries Ltd.
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. Torrent Pharmaceuticals Ltd.
  • 19.25. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ICOSAPENT ETHYL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER SOFTGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER SOFTGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ETHYL ESTER SOFTGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH STATINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH STATINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH STATINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH OTHER LIPID MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH OTHER LIPID MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ICOSAPENT ETHYL WITH OTHER LIPID MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINICAL TRIAL SUPPLIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINICAL TRIAL SUPPLIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINICAL TRIAL SUPPLIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMPOUNDED PREPARATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMPOUNDED PREPARATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMPOUNDED PREPARATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIABETES WITH CARDIOVASCULAR RISK FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIABETES WITH CARDIOVASCULAR RISK FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIABETES WITH CARDIOVASCULAR RISK FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SEVERE HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SEVERE HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SEVERE HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY MILD TO MODERATE HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY MILD TO MODERATE HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY MILD TO MODERATE HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PURE ICOSAPENT ETHYL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RESEARCH AND COMPOUNDING PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)